Theravance Biopharma, Inc. (TBPH) intrinsic value & 10-year financials
Theravance Biopharma, Inc. (TBPH) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 9.2% a year to $107.5M, with an average return on invested capital of -86.7%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $107.5M
- Revenue growth (10-yr CAGR)
- 9.2%
- ROIC (10-yr avg)
- -86.7%
- Free cash flow (FY2025)
- $238.5M
TBPH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $107.5M | $105.9M | $2.06 | $238.5M | -3.4% | -1.7% |
| FY2024 | $64.4M | -$56.4M | -$1.15 | -$11.9M | -72.9% | -23.7% |
| FY2023 | $57.4M | -$55.2M | -$1.00 | -$29.5M | -97.6% | -27.5% |
| FY2022 | $51.3M | $872.1M | $11.85 | -$187.6M | -179.1% | -42.8% |
| FY2021 | $55.3M | -$199.4M | -$2.87 | -$211.3M | -466.1% | -98.8% |
| FY2020 | $71.9M | -$278.0M | -$4.46 | -$257.0M | -414.4% | -115.1% |
| FY2019 | $73.4M | -$236.5M | -$4.25 | -$241.4M | -343.1% | -200.7% |
| FY2018 | $60.4M | -$215.5M | — | -$120.1M | -395.5% | -165.7% |
| FY2017 | $15.4M | -$285.4M | — | -$203.5M | -1690.6% | -104.1% |
| FY2016 | $48.6M | -$190.7M | — | -$101.1M | -371.0% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Theravance Biopharma, Inc. is a consistent compounder, expanding top-line revenue at 9.2% annually over the past decade.
Theravance Biopharma, Inc. has historically struggled to out-earn its cost of capital, averaging just -46.4% ROIC.
Theravance Biopharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Theravance Biopharma, Inc. is modeled at -44.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-141.97 per share.